50% Off Your Order*

Easter Savings!!

Take 50% Off!
Buy 2 Get 1 Free

Blend CJC 1295 NO DAC 5MG with GHRP-6 5MG

Availability: In stock

$0.00
  • Free Priority Shipping
  • With Purchase over $99 | USA ONLY

Buy 2 Get 1 Free Blend CJC 1295 NO DAC 5MG with GHRP-6 5MG :

Unit Size 10 mg/ vial
Unit Quantity 1 vial
Purity (Mass Spectrometry and UV) 99.0%
Appearance Lyophilized White Powder
Source Chemical Synthesis
Storage
Lyophilized Blend CJC 1295 NO DAC with GHRP-6 is Stable
at roomTemperature for 90 days, however it is best to store in a freezer
below - 8c for any extended period of time. After reconstitution
Blend CJC 1295 NO DAC with GHRP-6 should be
refrigerated at temperatures not to exceed 35 F.
Terms The products we offer are intended for laboratory
research use only. Please familiarize yourself with
our terms of service prior to ordering.

 

CJC 1295 NO/DAC with GHRP-6 is a synthetic analog of the growth hormone-releasing hormone (GHRH). This specific formulation also contains growth hormone-releasing peptide-6 (GHRP-6). This peptide is derived from GHRH 1-29, another synthetic peptide also known as sermorelin. CJC-1295 contains 30 amino acids and has a molecular weight of 3647.16 g/mol. CJC-1295 can be formulated with or without the drug affinity complex (DAC), which was designed originally to improve the half-life of the peptide. This allows it to bioconjugate with albumin in the bloodstream, preventing its degradation and increasing its therapeutic window.1 Endogenous GHRH has a half-life of around 7 minutes.2 However, this formulation does not have the DAC attached to CJC-1295. One study using a mouse model with GHRH knocked out found that CJC-1295 treatment causes normal growth hormone release without interfering with downstream pathways, such as insulin-like growth factor-1 (IGF-1) release.3 This allows researchers to utilize the peptide in a biologically relevant setting. GHRP-6 is a synthetic analog of ghrelin, which functions endogenously to release growth hormone and stimulate appetite. It binds to the growth hormone secretagogue receptor (GHS-R). Since CJC-1295 and GHRP-6 have similar functions, many studies have found that these peptides can work synergistically to increase growth hormone levels. Since CJC-1295 does not interfere with the pulsatile release of growth hormone, it can be combined with GHRP-6 to enhance baseline levels.4,5 Studies show that together, these peptides play a role in promoting muscle and bone strength, along with enhanced wound healing and recovery from stroke.4,6,7 While studies have used CJC-1295 and GHRP-6, this formulation is not approved for these purposes. CJC-1295 NO/DAC with GHRP-6 is for laboratory research use only. It is available at a concentration of 5mg X 2 = 10mg per vial for use in vitro studies.

References: 1. Jette L, Leger R, Thibaudeau K, et al. Human Growth Hormone-Releasing Factor (hGRH) 1-29 - Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005 Jul;146(7):3052-3058. 2. Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. 3.Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. 4. Mayola MF, Betancourt L, Molina-Kautzman A, et al. Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study. Int Wound J. 2018 Aug;15(4):538-546. 5. Huang H, Chen X, Han Q, et al. The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice. Neuropharmacology. 2019 Sep;155:31-43. 6. Mari YM, Mayola MF, Barreto AA, et al. Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds. Plast Surg Int. 2016;2016:4361702. 7. Subiros N, Perez-Saad HM, Berlanga JA, et al. Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurol Res. 2016 Mar;38(3):187-95.